NanoViricides, Inc. is pioneering the development of broad-spectrum nanoviricides, which are innovative antiviral therapeutics designed to target and neutralize a wide range of viruses. These nanoviricides function by mimicking the natural receptors on host cells, allowing them to bind to viruses effectively. Once attached, the nanoviricides encapsulate the virus, leading to its destruction by dismantling its structure and preventing it from infecting host cells. This technology is particularly notable for its ability to address multiple points of attack on a virus particle, which contrasts with traditional antibodies that typically target only one or two sites. As a result, NanoViricides aims to create treatments that are effective against a vast array of viral strains, including those that may mutate over time.

The versatility of NanoViricides' platform technology allows for the rapid design and optimization of antiviral agents tailored to specific viruses or groups of viruses. By chemically attaching virus-binding ligands to flexible polymer nanomicelles, the company can create targeted therapeutics that not only disrupt the extracellular viral lifecycle but also inhibit the intracellular replication of viruses. This dual-action approach positions nanoviricides as a potential game-changer in the field of antiviral therapy, with applications against significant viral threats such as HIV, Influenza, Dengue, and Ebola. The broad-spectrum capability of these nanoviricides, which can potentially bind to 90-95% of known viruses, underscores their promise in addressing both common and neglected viral diseases.

United States

NanoViricides, Inc. makesnanoviricides®. Nanoviricides are nanoparticles designed to protect cells from infection by acting as decoys. Virusesbind to nanoviricides instead of cell-surface receptors, gettrapped, and become neutralized.NanoViricides is working to developa treatment for COVID-19 using its nanoviricide®technology.

NanoViricides

Company Details